Literature DB >> 19794087

Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen.

Els Lierman1, Helen Van Miegroet, Els Beullens, Jan Cools.   

Abstract

Protein tyrosine kinases form a large family of signaling proteins implicated in both normal and malignant cell signaling. The aim of this study was to identify protein tyro-sine kinases that can transform hematopoietic cells to growth factor independent proliferation when constitutively activated by homodimerization. We used a modified retroviral insertion mutagenesis screen with a retroviral vector containing the homodimerization domain of ETV6 followed by an artificial splice donor site. Integration of this retroviral vector within a gene of the host genome would generate a fusion transcript containing the dimerization domain and part of the disrupted gene. Using this strategy with the IL3 dependent Ba/F3 cell line, we identified 8 different protein tyrosine kinases (Abl1, Fgfr1, Hck, Jak2, Lck, Mertk, Mst1r, Tnk1) that transformed the cells. These results characterize HCK, MERTK, MST1R and TNK1 as potential oncogenes and describe a method to identify gain-of-function fusion genes using a retroviral insertion screen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19794087      PMCID: PMC2754961          DOI: 10.3324/haematol.2009.007328

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  19 in total

1.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 2.  Tyrosine kinases as targets for cancer therapy.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck.

Authors:  J M Lionberger; M B Wilson; T E Smithgall
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.

Authors:  A K Keating; D B Salzberg; S Sather; X Liang; S Nickoloff; A Anwar; D Deryckere; K Hill; D Joung; K K Sawczyn; J Park; D Curran-Everett; L McGavran; L Meltesen; L Gore; G L Johnson; D K Graham
Journal:  Oncogene       Date:  2006-05-01       Impact factor: 9.867

6.  Thirty-eight-negative kinase 1 (TNK1) facilitates TNFalpha-induced apoptosis by blocking NF-kappaB activation.

Authors:  N Azoitei; A Brey; T Busch; S Fulda; G Adler; T Seufferlein
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

7.  Kos1, a nonreceptor tyrosine kinase that suppresses Ras signaling.

Authors:  Kishalay Hoare; Sarasija Hoare; Orla M Smith; Grace Kalmaz; Donald Small; W Stratford May
Journal:  Oncogene       Date:  2003-06-05       Impact factor: 9.867

8.  BCR/ABL confers growth factor independence upon a murine myeloid cell line.

Authors:  R A Mandanas; H S Boswell; L Lu; D Leibowitz
Journal:  Leukemia       Date:  1992-08       Impact factor: 11.528

9.  Retroviral DNA integration: viral and cellular determinants of target-site selection.

Authors:  Mary K Lewinski; Masahiro Yamashita; Michael Emerman; Angela Ciuffi; Heather Marshall; Gregory Crawford; Francis Collins; Paul Shinn; Jeremy Leipzig; Sridhar Hannenhalli; Charles C Berry; Joseph R Ecker; Frederic D Bushman
Journal:  PLoS Pathog       Date:  2006-06-23       Impact factor: 6.823

Review 10.  Dysregulation of the protein tyrosine kinase LCK in lymphoproliferative disorders and in other neoplasias.

Authors:  M B Majolini; M Boncristiano; C T Baldari
Journal:  Leuk Lymphoma       Date:  1999-10
View more
  10 in total

1.  MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context.

Authors:  Maria Kleppe; Nicole Mentens; Thomas Tousseyn; Iwona Wlodarska; Jan Cools
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

2.  Thirty-eight-negative kinase 1 mediates trauma-induced intestinal injury and multi-organ failure.

Authors:  Milena Armacki; Anna Katharina Trugenberger; Ann K Ellwanger; Tim Eiseler; Christiane Schwerdt; Lucas Bettac; Dominik Langgartner; Ninel Azoitei; Rebecca Halbgebauer; Rüdiger Groß; Tabea Barth; André Lechel; Benjamin M Walter; Johann M Kraus; Christoph Wiegreffe; Johannes Grimm; Annika Scheffold; Marlon R Schneider; Kenneth Peuker; Sebastian Zeißig; Stefan Britsch; Stefan Rose-John; Sabine Vettorazzi; Eckhart Wolf; Andrea Tannapfel; Konrad Steinestel; Stefan O Reber; Paul Walther; Hans A Kestler; Peter Radermacher; Thomas Fe Barth; Markus Huber-Lang; Alexander Kleger; Thomas Seufferlein
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

3.  High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

Authors:  Meredith C Henderson; Irma M Gonzales; Shilpi Arora; Ashish Choudhary; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses; David O Azorsa
Journal:  Mol Cancer Res       Date:  2011-05-02       Impact factor: 5.852

Review 4.  Tnk1/Kos1: a novel tumor suppressor.

Authors:  William Stratford May; Kishalay Hoare; Sarasija Hoare; Mary K Reinhard; Young J Lee; S Paul Oh
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

5.  Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.

Authors:  J S Waizenegger; I Ben-Batalla; N Weinhold; T Meissner; M Wroblewski; M Janning; K Riecken; M Binder; D Atanackovic; H Taipaleenmaeki; D Schewe; S Sawall; V Gensch; M Cubas-Cordova; A Seckinger; W Fiedler; E Hesse; N Kröger; B Fehse; D Hose; B Klein; M S Raab; K Pantel; C Bokemeyer; S Loges
Journal:  Leukemia       Date:  2014-08-08       Impact factor: 11.528

6.  Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells.

Authors:  Nataly Kacherovsky; Michael A Harkey; C Anthony Blau; Cecilia M Giachelli; Suzie H Pun
Journal:  Nucleic Acids Res       Date:  2012-03-08       Impact factor: 16.971

7.  Drosophila activated Cdc42 kinase has an anti-apoptotic function.

Authors:  Jessica A Schoenherr; J Michelle Drennan; Juan S Martinez; Madhusudana Rao Chikka; Mark C Hall; Henry C Chang; James C Clemens
Journal:  PLoS Genet       Date:  2012-05-17       Impact factor: 5.917

Review 8.  Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Authors:  Sandrine Medves; Jean-Baptiste Demoulin
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

Review 9.  Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.

Authors:  Dan Yan; H Shelton Earp; Deborah DeRyckere; Douglas K Graham
Journal:  Cancers (Basel)       Date:  2021-11-11       Impact factor: 6.639

10.  Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.

Authors:  Koen Debackere; Lukas Marcelis; Sofie Demeyer; Marlies Vanden Bempt; Nicole Mentens; Olga Gielen; Kris Jacobs; Michael Broux; Gregor Verhoef; Lucienne Michaux; Carlos Graux; Iwona Wlodarska; Philippe Gaulard; Laurence de Leval; Thomas Tousseyn; Jan Cools; Daan Dierickx
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.